LLY analyst scorecard · Lilly (Eli)
58 rating actions on LLY in the last 12 months. Of 71 price targets that resolved, 29 were reached while they stood, 40 were replaced by the same firm first, and 2 fell short at their deadline. Ratings: 93% Buy-type, 3% Hold-type, 3% Sell-type. Consensus target $1337, 2% below the last close.
Checked through 2026-10-29 · last close $1368.23 (2026-10-29). Rebuilt every morning.
What the Holds say: 2 Hold-type ratings on LLY in the last 12 months carried a median target -1% from the price on the day; 50% sat below it.
Firm by firm
| Firm | Latest rating | Date | Latest target | Targets reached | Replaced early | Resolved | Ratings vs sector |
|---|---|---|---|---|---|---|---|
| Bank of America | Buy | 2026-07-10 | $1334 | 1 | 3 | 5 | 1 of 1 |
| Guggenheim | Buy | 2026-09-18 | $1284 | 6 | 7 | 13 | 1 of 1 |
| Morgan Stanley | Overweight | 2026-10-07 | $1430 | 0 | 8 | 8 | 1 of 1 |
| JPMorgan | Overweight | 2026-09-28 | $1500 | 0 | 5 | 5 | 1 of 1 |
| Cantor Fitzgerald | Overweight | 2026-10-08 | $1440 | 2 | 5 | 7 | 1 of 1 |
| Leerink Partners | Outperform | 2026-10-21 | $1316 | 2 | 0 | 2 | — |
| Citigroup | Buy | 2026-07-15 | $1600 | 0 | 2 | 2 | 1 of 1 |
| Bernstein | Outperform | 2026-07-14 | $1385 | 0 | 1 | 1 | — |
| UBS | Buy | 2026-07-13 | $1425 | 2 | 1 | 3 | 1 of 1 |
| BMO Capital | Outperform | 2025-12-04 | $1200 | 2 | 0 | 2 | — |
| TD Cowen | Buy | 2026-09-22 | $1250 | 1 | 0 | 1 | — |
| Jefferies | Buy | 2026-06-09 | $1350 | 1 | 0 | 1 | — |
| Wolfe Research | Outperform | 2026-05-04 | $1325 | 2 | 0 | 2 | 1 of 1 |
| HSBC | Reduce | 2026-09-10 | $940 | 1 | 1 | 2 | — |
| Barclays | Overweight | 2026-05-05 | $1400 | 0 | 1 | 2 | 1 of 1 |
| Truist Securities | Buy | 2026-08-07 | $1376 | 2 | 1 | 3 | 1 of 1 |
| Wells Fargo | Overweight | 2026-08-06 | $1330 | 2 | 3 | 5 | 1 of 1 |
| RBC Capital | Outperform | 2026-10-12 | $1500 | 0 | 1 | 1 | — |
| Freedom Broker | Buy | 2026-02-10 | $1200 | 1 | 0 | 1 | — |
| Deutsche Bank | Buy | 2026-02-09 | $1285 | 2 | 1 | 3 | 1 of 1 |
Counts for one firm on one stock are small and move together; they are a record, not a grade. Neither the firms nor LLY carry a letter here. Why →
Every call, last 12 months
| Date | Firm | Rating | Action | Price at call | Target | Target status | Move in the 30 days before |
|---|---|---|---|---|---|---|---|
| 2026-10-21 | Leerink Partners | Outperform | maintained | $1270.75 | $1316 | within 5% of price when set | +9.1% |
| 2026-10-12 | RBC Capital | Outperform | reiterated | $1182.62 | $1500 | running to 2027-10-12 | +6.0% |
| 2026-10-08 | Cantor Fitzgerald | Overweight | maintained | $1169.60 | $1440 | running to 2027-10-08 | +4.1% |
| 2026-10-07 | Morgan Stanley | Overweight | maintained | $1188.72 | $1430 | running to 2028-04-07 | +3.4% |
| 2026-09-28 | JPMorgan | Overweight | maintained | $1184.78 | $1500 | running to 2027-09-28 | +0.9% |
| 2026-09-22 | TD Cowen | Buy | reiterated | $1170.14 | $1250 | reached 2026-10-15 | -6.8% |
| 2026-09-18 | Guggenheim | Buy | maintained | $1152.93 | $1284 | reached 2026-10-22 | -9.9% |
| 2026-09-10 | HSBC | Reduce | maintained | $1123.00 | $940 | running to 2027-09-10 | -7.6% |
| 2026-08-07 | Truist Securities | Buy | maintained | $1185.71 | $1376 | running to 2027-08-07 | -2.5% |
| 2026-08-06 | Wells Fargo | Overweight | maintained | $1191.94 | $1330 | reached 2026-10-29 | -3.5% |
| 2026-08-06 | Cantor Fitzgerald | Overweight | maintained | $1191.94 | $1410 | replaced 2026-10-08, new $1440 | -3.5% |
| 2026-07-15 | Citigroup | Buy | maintained | $1156.63 | $1600 | running to 2027-07-15 | +2.4% |
| 2026-07-14 | Bernstein | Outperform | maintained | $1152.54 | $1385 | running to 2027-07-14 | +1.7% |
| 2026-07-13 | UBS | Buy | maintained | $1181.87 | $1425 | running to 2027-07-13 | +4.3% |
| 2026-07-13 | Guggenheim | Buy | maintained | $1181.87 | $1273 | reached 2026-08-19 | +4.3% |
| 2026-07-10 | Bank of America | Buy | maintained | $1188.58 | $1334 | reached 2026-10-29 | +4.6% |
| 2026-07-08 | Truist Securities | Buy | maintained | $1215.83 | $1370 | replaced 2026-08-07, new $1376 | +5.8% |
| 2026-07-08 | Morgan Stanley | Overweight | maintained | $1215.83 | $1347 | replaced 2026-10-07, new $1430 | +5.8% |
| 2026-07-08 | RBC Capital | Outperform | maintained | $1215.83 | $1500 | running to 2027-07-08 | +5.8% |
| 2026-07-07 | JPMorgan | Overweight | maintained | $1235.56 | $1400 | replaced 2026-09-28, new $1500 | +9.2% |
| 2026-07-06 | Cantor Fitzgerald | Overweight | maintained | $1200.06 | $1350 | replaced 2026-08-06, new $1410 | +6.1% |
| 2026-06-25 | Leerink Partners | Outperform | maintained | $1127.69 | $1232 | reached 2026-07-07 | +5.9% |
| 2026-06-09 | Jefferies | Buy | maintained | $1144.68 | $1350 | reached 2026-10-29 | +20.7% |
| 2026-05-26 | Bank of America | Buy | maintained | $1064.74 | $1251 | replaced 2026-07-10, new $1334 | +20.4% |
| 2026-05-05 | Barclays | Overweight | maintained | $988.87 | $1400 | running to 2027-05-05 | +5.7% |
| 2026-05-05 | Guggenheim | Buy | reiterated | $988.87 | $1183 | reached 2026-06-26 | +5.7% |
| 2026-05-04 | Wolfe Research | Outperform | reiterated | $967.93 | $1325 | reached 2026-10-29 | +3.5% |
| 2026-05-01 | Cantor Fitzgerald | Overweight | maintained | $963.33 | $1230 | replaced 2026-07-06, new $1350 | +0.9% |
| 2026-04-22 | Guggenheim | Buy | maintained | $921.48 | $1183 | reached 2026-06-26 | +1.2% |
| 2026-04-10 | Morgan Stanley | Overweight | maintained | $939.47 | $1327 | replaced 2026-07-08, new $1347 | -6.0% |
| 2026-04-02 | Bank of America | Buy | maintained | $935.58 | $1294 | replaced 2026-05-26, new $1251 | -7.2% |
| 2026-03-30 | Guggenheim | Buy | maintained | $886.63 | $1163 | replaced 2026-04-22, new $1183 | -15.7% |
| 2026-03-17 | HSBC | Hold → Reduce | downgrade | $930.35 | $850 | replaced 2026-09-10, new $940 | -10.5% |
| 2026-02-25 | RBC Capital | Outperform | initiated | $1028.83 | $1250 | replaced 2026-07-08, new $1500 | -3.2% |
| 2026-02-20 | Barclays | Overweight | initiated | $1009.52 | $1350 | replaced 2026-05-05, new $1400 | -6.4% |
| 2026-02-10 | Freedom Broker | Hold → Buy | upgrade | $1025.00 | $1200 | reached 2026-06-26 | -3.6% |
| 2026-02-09 | Deutsche Bank | Buy | maintained | $1044.67 | $1285 | reached 2026-10-22 | -1.8% |
| 2026-02-05 | JPMorgan | Overweight | maintained | $1020.84 | $1300 | replaced 2026-07-07, new $1400 | -4.1% |
| 2026-02-05 | Cantor Fitzgerald | Overweight | maintained | $1020.84 | $1205 | replaced 2026-05-01, new $1230 | -4.1% |
| 2026-02-05 | Wells Fargo | Overweight | maintained | $1020.84 | $1280 | replaced 2026-08-06, new $1330 | -4.1% |
| 2026-02-05 | Morgan Stanley | Overweight | maintained | $1020.84 | $1313 | replaced 2026-04-10, new $1327 | -4.1% |
| 2026-02-02 | Freedom Broker | Hold | maintained | $1044.13 | $1050 | within 5% of price when set | -3.4% |
| 2026-01-20 | Guggenheim | Buy | maintained | $1041.29 | $1161 | replaced 2026-03-30, new $1163 | -2.8% |
| 2025-12-15 | Bank of America | Buy | maintained | $1062.19 | $1268 | replaced 2026-04-02, new $1294 | +3.6% |
| 2025-12-10 | Wells Fargo | Overweight | maintained | $993.64 | $1200 | replaced 2026-02-05, new $1280 | +2.8% |
| 2025-12-04 | BMO Capital | Outperform | maintained | $1014.49 | $1200 | reached 2026-06-26 | +11.9% |
| 2025-12-03 | Guggenheim | Buy | maintained | $1033.56 | $1163 | replaced 2026-01-20, new $1161 | +15.3% |
| 2025-11-24 | Morgan Stanley | Overweight | maintained | $1070.16 | $1290 | replaced 2026-02-05, new $1313 | — |
| 2025-11-24 | Bernstein | Outperform | maintained | $1070.16 | $1300 | replaced 2026-07-14, new $1385 | — |
| 2025-11-19 | Truist Securities | Buy | maintained | $1049.60 | $1182 | reached 2026-06-26 | — |
| 2025-11-18 | JPMorgan | Overweight | maintained | $1030.05 | $1150 | replaced 2026-02-05, new $1300 | — |
| 2025-11-13 | Morgan Stanley | Overweight | maintained | $1022.87 | $1171 | replaced 2025-11-24, new $1290 | — |
| 2025-11-12 | Citigroup | Buy | maintained | $1017.78 | $1500 | replaced 2026-07-15, new $1600 | — |
| 2025-11-10 | Freedom Broker | Buy → Hold | downgrade | $966.64 | $950 | within 5% of price when set | — |
| 2025-11-10 | Leerink Partners | Market Perform → Outperform | upgrade | $966.64 | $1104 | reached 2025-11-25 | — |
| 2025-11-07 | UBS | Buy | maintained | $924.37 | $1080 | reached 2025-11-25 | — |
| 2025-11-06 | BMO Capital | Outperform | maintained | $937.44 | $1100 | reached 2025-11-25 | — |
| 2025-10-31 | Cantor Fitzgerald | Overweight | maintained | $862.86 | $985 | reached 2025-11-11 | — |
Also in Pharma
Interactive version with the price chart and target overlay: Scorecard tab on the dashboard. All covered names: index.
How calls are checked
Every call is checked on the firm's own terms. A price target is followed until its own deadline (12 months unless the firm publishes a different horizon) and ends as reached (the stock closed at or beyond it while it stood), replaced (the same firm set a new target first) or short at deadline. A rating is compared with the stock's sector SPDR ETF on total return over the rating's life, because most big-firm ratings are relative: Overweight means "beat its peers", not "go up". Hold-type ratings are tracked, not graded. A firm is numbered only with 30+ resolved targets, and a letter prints only for a firm's whole record where an exact test separates it from a coin flip. None of this is a verdict on anyone's skill, and one day is never a grade. The full method →
Get the daily brief
Our take, the S&P 500 Pulse, the Street's calls and today's docket — one email, weekdays, 9 AM ET, 30 minutes before the open.